RELAPSED CANCER
Clinical trials for RELAPSED CANCER explained in plain language.
Never miss a new study
Get alerted when new RELAPSED CANCER trials appear
Sign up with your email to follow new studies for RELAPSED CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug combo aims to wipe out Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) can safely make chronic lymphocytic leukemia (CLL) disappear to undetectable levels in patients whose cancer has returned or not responded to prior treatments. About 64 …
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
New drug combo shows promise for hard-to-treat lymphoma
Disease control Recruiting nowThis study tests a new combination of the drug epcoritamab plus chemotherapy (GDP) in 32 adults with relapsed or refractory large B-cell lymphoma. The goal is to see if this combo can shrink tumors enough to allow patients to proceed to a stem cell transplant or CAR T-cell therap…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New drug duo offers hope for hard-to-treat brain lymphoma
Disease control Recruiting nowThis study tests a combination of two drugs, zanubrutinib and pemetrexed, followed by zanubrutinib alone, in 15 people with relapsed or refractory central nervous system lymphoma. The goal is to see if this treatment can control the disease and how safe it is. Participants must h…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New cocktail aims to tame Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combination can stop the cancer from growing for at least 6…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New hope for hard-to-treat blood cancers: experimental combo therapy enters human trials
Disease control Recruiting nowThis study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like certain lymphomas) that have returned or stopped responding to standard therapy. The goal is to…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New study aims to bring myeloma treatment home, easing hospital visits and caregiver stress
Disease control Recruiting nowThis study looks at whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely in an outpatient clinic instead of the hospital. It involves 15 adults who have tried at least three prior treatments. The goal is to create written guidelines for out…
Matched conditions: RELAPSED CANCER
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC